Shandong Lukang Pharmaceutical Co.,Ltd. operates as a pharmaceutical company in China. The company offers systemic anti-infectives, hypoglycemic agents, cardiov...
LKPC's application for the issuance of stocks to specific objects has been approved for registration by the China Securities Regulatory Commission
LKPC plans to acquire equity in Hecheng Company to further optimize resource allocation
LKPC: Net profit in the first half of 2025 decreased by 64.38% year-on-year
LKPC's subsidiary has obtained the drug registration certificate for Vardenafil Hydrochloride Tablets
LKPC: It is expected that the net profit in the first half of 2025 will decrease by 59.34%-65.98% year-on-year
LKPC: Gefitinib tablets and gefitinib raw materials have been approved separately